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Divaka Perera, MA, MD*
London, and Leeds, United KingdomObjectives This study sought to identify the effect of coronary autoregulation on myocardial
perfusion during intra-aortic balloon pump (IABP) therapy.
Background IABP is the most commonly used circulatory support device, although its efﬁcacy in
certain scenarios has been questioned. The impact of alterations in microvascular function on IABP
efﬁcacy has not previously been evaluated in humans.
Methods Thirteen patients with ischemic cardiomyopathy (left ventricular ejection fraction: 34  8%)
undergoing percutaneous coronary intervention were recruited. Simultaneous intracoronary pressure
and Doppler-ﬂow measurements were undertaken in the target vessel following percutaneous
coronary intervention, during unassisted and IABP-assisted conditions. Coronary autoregulation was
modulated by the use of intracoronary adenosine, inducing maximal hyperemia. Wave intensity
analysis characterized the coronary wave energies associated with balloon counterpulsation.
Results Two unique diastolic coronary waves were temporally associated with IABP device use;
a forward compression wave and a forward expansion wave caused by inﬂation and deﬂation,
respectively. During basal conditions, IABP therapy increased distal coronary pressure (82.4  16.1
vs. 88.7  17.8 mm Hg, p ¼ 0.03), as well as microvascular resistance (2.32  0.52 vs. 3.27  0.41
mm Hg cm s–1, p ¼ 0.001), with no change in average peak velocity (30.6  12.0 vs. 26.6  11.3 cm s–1,
p ¼ 0.59). When autoregulation was disabled, counterpulsation caused an increase in average peak
velocity (39.4  10.5 vs. 44.7  17.5 cm s–1, p ¼ 0.002) that was linearly related with IABP–forward
compression wave energy (R2 ¼ 0.71, p ¼ 0.001).
Conclusions Autoregulation ameliorates the effect of IABP on coronary ﬂow. However, during
hyperemia, IABP augments myocardial perfusion, principally due to a diastolic forward compression
wave caused by balloon inﬂation, suggesting IABP would be of greatest beneﬁt when microcirculatory
reserve is exhausted. (J Am Coll Cardiol Intv 2014;7:631–40) ª 2014 by the American College of
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632In excess of one-third of all coronary revascularization pro-
cedures occur in the context of underlying impaired left
ventricular function, with an associated increase in morbidity
and mortality (1–3). The intra-aortic balloon pump (IABP) is
commonly used during percutaneous coronary intervention
(PCI) with the aim of increasing coronary blood ﬂow
through augmentation of the diastolic aortocoronary
pressure gradient. Additionally, IABP therapy decreases
myocardial oxygen demand, by reducing the end-diastolic
pressure, and, therefore, the afterload, making it an attractive
means of ameliorating ischemia and consequently enhancing
cardiac output. However, recent randomized control data,
in clinical scenarios where IABP therapy is commonly
employed, have shown limited efﬁcacy with routine place-
ment of the device (4–6). The physiological basis for this
lack of beneﬁt remains unclear, but it may relate to theand the National Institute for Health
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Abbreviations
and Acronyms
APV = average peak velocity
BEW = backward expansion
waves
DTI = diastolic time index
FCW = forward compression
wave
FEW = forward expansion
wave
IABP = intra-aortic balloon
pump
Pa = aortic pressure
PCI = percutaneous coronary
intervention
Pd = intracoronary pressure
TTI = tension time index
WIA = wave intensity
analysisinteraction of the device with
the innate homeostatic coronary
autoregulatory mechanisms that
govern myocardial perfusion,
particularly in regard to the vaso-
motor control at the level of the
microcirculatory resistance ves-
sels. IABP therapy may only
provide additional hemodynamic
support when myocardial perfu-
sion is outside the normal physio-
logical range, when autoregulation
has been pathologically disabled,
in conditions such as profound
cardiogenic shock or persistent
ischemia.
Regional and global left ven-
tricular perfusion and function
are closely related to the micro-
vascular integrity of the relevant
myocardial territories, with micro-vascular dysfunction leading to left ventricular impairment
and vice versa. The advent of pressure and Doppler sensor-
tipped guidewire technology has allowed detailed in vivo
interrogation of microcirculatory physiology (7,8). Wave
intensity analysis (WIA) of phasic coronary pressure and
ﬂow proﬁles has allowed further characterization of the
microcirculation and its impact on coronary ﬂow in aResearch Biomedical Research Centre at Guy’s
Service Foundation Trust and King’s College
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13; revised manuscript received November 11,number of stable and acute clinical settings (9–11). These
studies demonstrate that mechanical impedance of the
coronary microcirculation by the myocardium is the pre-
dominant factor that governs myocardial perfusion, with
a backward traveling (microcirculatory) expansion wave
(BEW), and a forward traveling (aortic) compression wave
(FCW) identiﬁed as being the most inﬂuential in generating
diastolic coronary ﬂow (12–14). WIA has not previously
been used in humans to assess the effect of IABP counter-
pulsation therapy on the energy transfer within the coro-
nary circulation.
The aim of this study was to characterize the effects of
IABP therapy on the coronary circulation by simultaneously
assessing coronary ﬂow, microvascular resistance, and wave
energy. Using these indices, we assessed whether microcir-
culatory autoregulation modulates the effects of IABP
therapy in patients with chronic ischemic cardiomyopathy
undergoing PCI.
Methods
Study population. Patients scheduled to undergo high-risk
single-vessel or multivessel PCI were considered for inclu-
sion in the study. High risk was deﬁned as the presence of
impaired left ventricular function (ejection fraction <40% on
cardiac magnetic resonance imaging, echocardiography, or
left ventricular angiography) and a large amount of
myocardium subtended by stenosed vessels, characterized by
the BCIS-JS (British Cardiovascular Intervention Society
Jeopardy Score) of 6 or greater. The BCIS-JS has been
described previously (15), but in brief, it is a modiﬁcation of
the Duke Jeopardy Score (16), which allows broader classi-
ﬁcation of coronary anatomy, including left main coronary
artery stenoses and bypass grafts (the total score ranges from
0 to 12). Exclusion criteria were a prior diagnosis of sig-
niﬁcant aortic valvular disease, nonischemic cardiomyopa-
thy, severe peripheral artery disease precluding insertion of
the IABP catheter, an acute coronary syndrome within the
preceding 48 h, or cardiogenic shock.
Cardiac catheterization, IABP, and intracoronary measurement
protocol. All patients were preloaded with aspirin
(300 mg) and clopidogrel (600 mg). Coronary angiography
was performed using a standard Judkins technique via a
femoral artery approach. A 40-cc IABP catheter (Maquet
Cardiovascular, Rastatt, Germany) was inserted via the
contralateral femoral artery and deployed in the descending
aorta distal to the left subclavian artery origin at the start
of the procedure and counterpulsation was commenced at
1:1 augmentation ratio. Intracoronary nitroglycerin was
administered before diagnostic angiography and intra-
coronary physiological measurements to ensure maximal
epicardial arterial vasodilation. Hemodynamic measurements
were obtained in the target vessel at least 5 min following
ﬁnal balloon occlusion during PCI. Aortic pressure (Pa) was
Figure 1. Arterial Pressure Waveform: Pulse Wave Parameters
Two systolic peaks are labeled P1 and P2. The area under the curve during
systole is the tension time index (TTI) and during diastole is diastolic time
index (DTI). Aug ¼ augmentation pressure; PP ¼ pulse pressure.
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633measured via the coronary guiding catheter. Intracoronary
pressure (Pd) and average peak velocity (APV) were
measured via a 0.014-inch dual pressure and Doppler sen-
sor-tipped guidewire (ComboWire, Volcano Corp., San
Diego, California), the tip being positioned in the distal
vessel. Simultaneous pressure and Doppler measurements
were repeated 3 for each condition to reduce acquisition
error, ensuring the resumption of steady state between mea-
surements, deﬁned as a return of APV to the baseline value.
First, basal measurements were obtained (with auto-
regulation “switched on”) during 1:1 IABP augmentation.
Then, measurements were obtained after transiently
disabling autoregulation, with 1:1 IABP augmentation.
Autoregulation was disabled by inducing maximal hyper-
emia via sequentially increasing doses of intracoronary
adenosine, with the maximal tolerable dose dictated by the
onset of atrioventricular conduction block or systemic
symptoms (up to 60 mg were administered in the right and
up to 96 mg in the left coronary arteries, respectively). Basal
and hyperemic measurements were then repeated in unas-
sisted conditions, after placing the IABP on “stand-by”
mode, and allowing at least 4 min for return of basal steady-
state conditions.
Data analysis. PHASIC PRESSURE AND FLOW ANALYSIS. Data
were sampled at 200 Hz and analyzed off-line, using a
customized program developed in Matlab (Mathworks, Inc.,
Natick, Massachusetts). A Savitzky-Golay convolution
method (17) was adopted, using a polynomial ﬁlter to reﬁne
the derivatives of the Pa and APV signals. Three to 6
consecutive cardiac cycles were selected for resting and
hyperemic conditions, gated on the electrocardiographic
R-wave peak, with ensemble averaging of Pa, Pd, APV, and
heart rate. For the purposes of WIA, it has been considered
that diastole commences with the onset of ventricular
relaxation, signiﬁed by the dicrotic notch on the arterial
pressure waveform, as previously described (14). Net coro-
nary wave intensity (dI) was calculated from the time-
derivatives (dt) of ensemble-averaged coronary pressure and
ﬂow velocity (U) as dI ¼ dPd/dt  dU/dt (10,18). Coin-
cident (microcirculation-derived) backward and (aorta-
derived) forward propagating waves were separated assuming
blood density to be 1,050 kg/m3 and estimating coronary
wave speed using the sum of squares method (18,19). The
peak energies (in W m–2 s–2  105) carried by the 3 most
prominent wave energies identiﬁed were analyzed. These
were the positive, aorta-derived FCW, occurring at the onset
of systole; the concurrently occurring negative, backward
(microcirculation-derived) compression wave, and BEW,
the ﬁrst negative wave occurring at the onset of ventricular
relaxation, identiﬁed by the onset of diastole. Additionally,
the waveforms that were associated with inﬂation and
deﬂation of the IABP balloon in diastole were also analyzed.
Total wave energy (area under the curve) was also deter-
mined to identify the relative changes occurring duringunassisted and IABP-assisted conditions. The investigators
who performed the data analyses were blinded to all clinical
patient data.
PULSE-WAVE AND MEAN-PER-BEAT PRESSURE-FLOW ANALYSIS.
Pulse wave analysis was performed using custom-made
programs (Matlab) in both unassisted and assisted aortic
arterial waveforms. The area under the systolic phase of the
pressure tracing (tension time index, TTI), and diastolic
phase, (diastolic time index, DTI), were determined using
the dicrotic notch (Fig. 1). TTI relates to myocardial oxygen
demand and DTI to coronary perfusion (20). The Buckberg
index was also calculated, providing a ratio of myocardial
oxygen supply and demand, which is the quotient of dia-
stolic to systolic pressure-time integral, representing the
potential relationship between subendocardial blood supply
(DTI) and afterload (TTI), respectively (20). To assess
the effect of the IABP device on the timing of the cardiac
cycle, diastolic time fraction was calculated. This represents
the ratio of time in diastole to duration of a complete heart
cycle.





where t represents time during the cardiac cycle from t-start to
t-end, vt is the instantaneous ﬂow velocity at time t, and dt
represents the interval between successive measurements.
Hyperemic and nonhyperemic (basal) microvascular
resistance were calculated as the ratio of mean Pd to APV
(mm Hg cm s–1) during maximal hyperemia or basal
conditions, respectively, obtained through simultaneous in-
tracoronary pressure-ﬂow measurements, during 3 to 6
consecutive cardiac cycles (8,21).
Table 1. Patient Characteristics




Diabetes mellitus 7 (64)
Hypercholesterolemia 10 (92)
Smokers 6 (54)
BMI, kg/m2 27  4
Prior MI 11 (100)
Previous PCI 5 (45)
Peripheral vascular disease 4 (36)
Left ventricular ejection fraction, % 34  8





Left main stem 4 (36)
Left anterior descending 7 (64)
Circumﬂex 4 (36)
Right coronary artery 5 (45)
BCIS-JS 9  2
Values are mean  SD or n (%).
BCIS-JS ¼ British Cardiovascular Intervention Society Jeopardy Score; BMI ¼ body mass
index; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; MI ¼ myocardial
infarction; PCI ¼ percutaneous coronary intervention.
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634Statistical analysis. Statistical analysis was performed using
IBM SPSS (version 20, Armonk, New York). D’Agostino
and Pearson omnibus normality test was performed to
ensure a nonskewed distribution. Two-way analysis of
variance without replication was performed for each
measured variable when comparing to 2 different (nomi-
nal) conditions. Correlation analysis was used to quantify the
relationship between variables. A 2-tail test for signiﬁcance
was performed in all analyses; p  0.05 was considered
statistically signiﬁcant. Data are represented as mean  SD,
unless otherwise stipulated.
Ethical approval. The study protocol was approved by the
U.K. National Health Service research ethics committee
(Reference: 11/H0804/10). All participants were provided
with an information sheet detailing the study protocol prior
to providing informed verbal and written consent.
Results
Baseline characteristics. Thirteen patients with ischemic
cardiomyopathy were recruited, 11 (age 67  11 years) with
a left ventricular ejection fraction of 34  8% completed the
study protocol. Two patients became hemodynamically
compromised during the procedure and did not complete
the study protocol and were therefore excluded from the
ﬁnal analysis. Of our study group, 82% (n ¼ 9) were hy-
pertensive, 91% (n ¼ 10) were hypercholesterolemic, and
all had prior myocardial infarction. The high-risk nature
of this cohort was typiﬁed by the elevated logistic Euro-
SCORE (European System for Cardiac Operative Risk
Evaluation) (11  5%) and signiﬁcant degree of coronary
artery disease burden, with a mean BCIS-JS of 9  2. Pa-
tient characteristics are outlined in Table 1.
Effects of hyperemia on unassisted coronary hemodynamics.
Heart rate and aortic and distal coronary pressures remained
unchanged during intracoronary adenosine-induced hyper-
emia (p ¼ 0.41, 0.93, and 0.26, respectively). There was a
reduction in microvascular resistance (R2 ¼ 0.61, p ¼ 0.003)
with a corresponding increase in coronary ﬂow (APV)
(R2 ¼ 0.62, p ¼ 0.01). Furthermore, there was an increase
in the microcirculatory BEW (R2 ¼ 0.57, p ¼ 0.02). Table 2
provides a summary of the hemodynamic observations.
IABP effects with “switched on” autoregulation. SYSTEMIC
AND PULSE WAVE PARAMETERS. During basal conditions,
heart rate remained unchanged following the introduction
of IABP device (66.3  14.1 vs. 66.4  12.3 beats/min, p ¼
0.87). Mean Pa altered signiﬁcantly with balloon-pump
assistance (92.2  16.4 vs. 95.4  20.4 mm Hg, p ¼ 0.03).
A nonsigniﬁcant trend in reduction of TTI was observed
(30.1  15.2 vs. 27.8  13.9, p ¼ 0.08) with balloon
augmentation. Whereas the device did not alter the
duration of diastole, with diastolic time fraction remaining
unchanged (0.65  0.07 vs. 0.64  0.08 s, p ¼ 0.87),
diastolic pressure-time index, DTI, increased in conjunctionwith diastolic augmentation of mean Pa with counter-
pulsation therapy (43.9  11.9 vs. 54.2  13.4, p ¼ 0.007).
The ratio of myocardial oxygen supply (DTI) to demand
(TTI), the Buckberg index, increased (1.70  0.68 vs. 2.08
 0.57, p ¼ 0.03).
MEAN CORONARY INDICES. Whereas balloon pump
augmentation led to an increase in distal coronary pressure
(82.4  16.1 vs. 88.7  17.8 mm Hg, p ¼ 0.04), there was
no corresponding change in mean ﬂow velocity (APV) (32.3
 11.1 vs. 26.6  11.3 cm s–1, p ¼ 0.08) in the presence of a
functioning autoregulation. Similarly, velocity time integral
remained unchanged during basal IABP-assisted conditions
(26.8  12.3 vs. 22.8  7.5 cm, p ¼ 0.51). Microvascular
resistance during basal conditions was observed to increase
signiﬁcantly during counterpulsation therapy (2.32  0.5
vs. 3.27  0.41 mm Hg cm s–1, p ¼ 0.001).
CORONARY WAVE INTENSITY ANALYSIS. The 3 previously
described wave energies (FCW, backward compression
wave, and BEW) were identiﬁed in all patients. Figure 2
demonstrates a typical coronary wave intensity proﬁle.
Additionally coronary WIA of the circulation during IABP
counterpulsation showed 2 additional wave energies (Fig. 3)
relating to the inﬂation and deﬂation of the balloon. Inﬂa-
tion resulted in an aortic-originating (forward traveling)
Table 2. Hemodynamic Characteristics
Basal (“Switched On” Autoregulation) Hyperemic (“Switched Off” Autoregulation)
Unassisted IABP-Assisted p Value Unassisted IABP-Assisted p Value
Mean-per-beat derivatives
HR, beats/min 66.3  14.1 66.4  12.3 0.87 69.2  14.2 69.1  12.6 0.85
Pa, mm Hg 92.6  17.4 95.4  20.4 0.03 93.4  16.4 92.1  15.4 0.01
Pd, mm Hg 82.4  16.1 88.7  17.8 0.04 82.4  16.1 89.7  14.4 0.02
APV, cm s–1 32.3  11.1 26.6  11.3 0.08 39.4  10.5* 44.7  17.5y 0.002
MR, mm Hg cm s–1 2.32  0.52 3.27  0.41 0.001 2.11  0.42* 2.25  0.78y 0.45
Pulse wave analysis
VTI, cm 26.8  12.3 22.8  7.5 0.51 25.8  15.1 32.4  15.7 0.009
DTF 0.65  0.07 0.64  0.08 0.87 0.60  0.09 0.61  0.09 0.33
DTI 43.9  11.9 54.2  13.4 0.007 39.5  13.0 46.5  14.5 0.01
TTI 30.1  15.2 27.8  6.8 0.08 31.4  11.6 27.9  8.7 0.11
BI 1.70  0.68 2.08  0.57 0.03 1.31  0.37 1.91  0.56 0.01
Wave intensity analysis, W m–2 s–2  105
Systolic wave energies
FCW þ1.70  0.40 þ1.82  0.51 0.27 þ1.75  0.46 þ1.78  0.55 0.34
BCW –0.32  0.20 –0.55  0.31 0.06 –0.48  0.25 –0.36  0.18 0.17
Diastolic wave energies
BEW –2.21  0.64 –1.62  0.67 0.004 –2.43  0.63* –1.98  0.76y 0.07
IABP-FCW N/A þ1.82  0.90 N/A N/A þ1.86  0.67 N/A
IABP-FEW N/A þ0.95  0.81 N/A N/A þ0.91  0.76 N/A
*Statistically signiﬁcant changes in parameters observed during unassisted basal versus hyperemic conditions (APV: p ¼ 0.01; MR: p ¼ 0.003; BEW: p ¼ 0.02). yStatistically signiﬁcant changes in parameters
observed during IABP-assisted basal versus hyperemic conditions (APV: p ¼ 0.005; MR: p ¼ 0.0001; BEW: p ¼ 0.03).
APV ¼ average peak velocity; BCW ¼ backward compression wave; BEW ¼ backward expansion wave; BI ¼ Buckberg index; DTF ¼ diastolic time fraction; DTI ¼ diastolic time integral; FCW ¼ forward
compression wave; FEW ¼ forward expansion wave; HR ¼ heart rate; IABP ¼ intra-aortic balloon pump; MR ¼ microvascular resistance; N/A ¼ not applicable; Pa ¼ mean aortic pressure; Pd ¼ mean distal
coronary pressure; TTI ¼ tension time index; VTI ¼ velocity time integral.
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635accelerating compression wave (IABP-FCW), with the
subsequent deﬂation of the balloon causing an aortic-origi-
nating (forward traveling) decelerating expansion wave
(IABP-FEW). Furthermore, during balloon-pump assis-
tance peak BEW was reduced compared with unassisted
conditions (–2.21  0.64 vs. –1.62  0.67 W m–2s–2  105,
p ¼ 0.004). During unassisted conditions, the relative
acceleratory energies provided by FCW and BEW were 39%
and 61%, respectively, whereas during IABP-assistance,
FCW was 36%, BEW reduced to 30%, with the IABP-
FCW accounting for 34% of total wave energy.
IABP effects with “switched off” autoregulation. SYSTEMIC
AND PULSE WAVE PARAMETERS. Balloon counterpulsation
during intracoronary adenosine-induced hyperemia did not
alter the heart rate (69.2  14.2 vs. 69.1  12.6 beats/min,
p ¼ 0.85), diastolic time fraction (0.60  0.09 vs. 0.61 
0.09 s, p ¼ 0.33), or mean Pa (93.4  16.4 vs. 92.1  15.4
mm Hg, p ¼ 0.57) compared with unassisted conditions.
TTI was reduced (although this was not statistically signif-
icant: 31.4  11.6 vs. 27.9  8.7, p ¼ 0.11), and there was
an increase in DTI (39.5  13.0 vs. 46.5  14.5, p ¼ 0.01),
with a corresponding increase in Buckberg index (1.31 
0.37 vs. 1.91  0.56, p ¼ 0.01), mirroring observations
during basal conditions.MEAN CORONARY INDICES. Similar to basal conditions,
balloon-pump assistance in the hyperemic setting was
accompanied by an increase in distal coronary pressure
(82.4  16.1 vs. 89.7  14.4 mm Hg, p ¼ 0.02). However,
in contrast to the basal state, there was an increase in
APV (39.4  10.5 vs. 44.7  17.5 cm s–1, p ¼ 0.002).
Furthermore, velocity time integral was observed to increase
during balloon assistance (25.8  15.1 vs. 32.4  15.7,
p ¼ 0.009). Hyperemic microvascular resistance was un-
changed in unassisted and assisted conditions (2.21  0.42
vs. 2.25  0.78 mm Hg cm s–1, p ¼ 0.45).
CORONARY WAVE INTENSITY ANALYSIS. Augmentation of
coronary ﬂow with balloon counterpulsation (DAPV ¼
APVIABP – APVunassisted) related proportionately with the
IABP-FCW wave energy (p ¼ 0.001, R2 ¼ 0.71) (Fig. 4)
with maximal hyperemia; there was no relationship between
these parameters in basal conditions. IABP-FEW also
related with augmentation of APV (p ¼ 0.003, R2 ¼ 0.60).
Multiple linear regression, conﬁrmed that augmentation
in APV was primarily as a result of IABP-FCW
(p ¼ 0.01) rather than IABP-FEW (p ¼ 0.14), with
DAPV ¼ 2.2  10–5(FEW) þ 5.7  10–5(FCW) þ 6.13.
The dominant microcirculatory wave, BEW, tended to
Figure 2. Coronary Wave Intensity Proﬁle
Demonstrates the 4 predominating wave energies present during a single
cardiac cycle, with the relative phasic coronary pressure and velocity trends
shown below the wave intensity analysis proﬁle. BCW ¼ backward
compression wave; BEW ¼ backward expansion wave; FCW ¼ forward
compression wave; FEW ¼ forward expansion wave.
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636decrease during hyperemic balloon-pump assistance (2.43
 0.63 vs. 1.98  0.76 W m–2 s–2  105, p ¼ 0.07)
compared with unassisted conditions.
Discussion
We have comprehensively characterized the effects of intra-
aortic balloon counterpulsation on coronary and microvas-
cular hemodynamics, including the ﬁrst clinical application
of coronary WIA in this setting. Using these techniques, we
have shown that the effects of IABP therapy are intimately
linked to innate microvascular function and that the pro-
cesses of autoregulation may ameliorate the potential bene-
ﬁts of this therapy. However, when autoregulation is
disabled, IABP therapy was seen to augment myocardial
perfusion. These ﬁndings help to explain the results of
recent randomized control trials of balloon counterpulsation
and also indicate the potential utility of this therapy in
clinical scenarios accompanied by exhausted microcirculatory
reserve.
Coronary autoregulation and IABP. Coronary blood ﬂow is
tightly controlled and matched to the oxygen demands of
the heart by adapting the caliber of the coronary resistance
arteries, via inter-related processes involving mechanisms
intrinsic to the vascular wall, as well as metabolic and
neurohumoral factors (22,23). The 2 major determinants of
coronary ﬂow are coronary arterial pressure and myocardialoxygen consumption. Coronary autoregulation is the
mechanism that maintains coronary ﬂow independent of
arterial pressure for a given level of oxygen consumption or
changing oxygen requirements at a constant perfusion
pressure (24). In the presence of an epicardial coronary
stenosis there is intramural microcirculatory vasodilation,
reduction in resistance, accommodating for the reduction in
pressure distal to the stenosis (25). Ischemia ensues as a
result of the inability of this vasodilatory response to match
the oxygen requirements, because the threshold of maximal
microcirculatory vasodilation has been exceeded, and resis-
tance cannot be reduced any further. Therefore in the
presence of persistent ischemia, the autoregulatory mecha-
nisms are completely exhausted, so that myocardial ﬂow
becomes proportional to perfusion pressure. This condition
of minimal resistance is mimicked by pharmacological
administration of adenosine, which causes maximal vasodi-
lation and reduction in microvascular resistance, switching
“off” the normal autoregulatory pathways. During this state,
we have demonstrated that IABP therapy leads to an in-
crease in distal coronary pressure, which proportionately
increases coronary ﬂow. However, when autoregulation is
intact, the counterpulsation-related increase in Pd is
accompanied by an increase in microvascular resistance, as
a consequence of which coronary ﬂow remains unchanged.
Clinical data on IABP efﬁcacy and the impact of
autoregulation. The efﬁcacy of IABP therapy has come in
to question in recent years in light of several randomized
control trials that have failed to demonstrate the efﬁcacy of
routine IABP placement in different clinical settings. The
ﬁrst of these was BCIS-1 (4), in which IABP was deployed
in patients who were hemodynamically stable at the outset,
but were at increased risk of major complications during
PCI, who showed no reduction in incidence of major
adverse cardiovascular and cerebrovascular events, compared
with those randomized to have unassisted PCI. Given that
most patients enrolled in BCIS-1 are likely to have had
perfusion pressures within the autoregulatory range and that
patients with active ischemia and shock were excluded, the
ﬁndings of the current study may explain why a strategy of
routine IABP placement in unselected patients failed to
show beneﬁt. On the other hand, 1 in 8 patients who were
randomized to receive unsupported PCI experienced he-
modynamic compromise sufﬁcient to warrant rescue IABP
insertion. There is a signal that those requiring “bail-out”
may be patients at the extreme end of the spectrum of
diminished physiological reserve, severity of coronary ar-
tery disease, and therefore microvascular dysfunction. The
CRISP AMI (Counterpulsation to Reduce Infarct Size
Pre-PCI Acute Myocardial Infarction) trial (26) assessed
the role of routine use of IABP in patients presenting with
large anterior STEMIs within 6 h of symptom onset
without cardiogenic shock. Pre-procedure IABP insertion
failed to reduce infarct size in this study. Although this result
Figure 3. IABP Wave Intensity Proﬁle
(A) Wave intensity analysis proﬁle during unassisted conditions demonstrating the 4 wave energies described in Figure 2. (B) Wave intensity analysis proﬁle during
intra-aortic balloon pump (IABP)-assisted conditions, highlighting the temporally related wave energies with device inﬂation (IABP-FCW) and deﬂation (IABP-FEW). Both
obtained with autoregulation “switched off” during hyperemia. Abbreviations as in Figure 2.
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637appears to be at odds with the physiological observations
seen in the current study, this lack of effect may have been
due to the relatively brief period of counterpulsation prior
to mechanical reperfusion being achieved. From our ob-
servations, the subgroup who stands to gain most beneﬁt
from counterpulsation therapy may be the one that had
persisting ischemia despite reperfusion. Analysis of this
subset of patients in CRISP-AMI may be instructive.Figure 4. IABP-FCW Relationship With Hyperemic Coronary Flow Velocity
During hyperemia, with autoregulation disabled, IABP device inﬂation is
associated with an acceleratory wave energy (IABP-FCW) that is linearly
related to coronary ﬂow (average peak velocity [APV]). Abbreviations as
in Figures 2 and 3.The most recent of these randomized clinical trials was
IABP-SHOCK II (Intra-aortic Balloon Support for
Myocardial Infarction With Cardiogenic Shock) (6), which
assessed the utility of IABP in acute myocardial infarc-
tion complicated by cardiogenic shock. A strategy of
elective IABP insertion failed to reduce 30-day mortality
in this study. Although hypotension is central to the clini-
cal diagnosis of cardiogenic shock, it is interesting to note
that systolic blood pressure was in excess of 90 mm Hg in
approximately 50% of all patients enrolled in IABP-
SHOCK II, falling within the normal range of coronary
autoregulation. Applying the observations of our current
study, it could be postulated that the presence of a work-
ing autoregulatory system may have limited the effect of
IABP therapy in many patients of the IABP-SHOCK II
cohort.
The effect of autoregulation on the efﬁcacy of me-
chanical hemodynamic support may also be applicable to
devices that aim to directly unload the left ventricular
cavity. Remmelink et al. (27) previously observed in a
cohort of patients undergoing PCI with left ventricular
dysfunction with adjunctive Impella device (Car-
diotechnik, Aachen, Germany) support that during basal
conditions, increased distal coronary pressure did not lead
to an augmentation of coronary ﬂow, though a linear
increase was evident during hyperemic conditions. Anal-
ogous with the current study, an increase in basal micro-
vascular resistance, due to the presence of a functioning
microcirculatory autoregulation, diminished the beneﬁcial
effect of the device.
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638Wave intensity analysis of IABP counterpulsation. Kolyva
et al. (28,29) previously demonstrated the effect of the
IABP balloon on aortic hemodynamics during in vivo and
ex vivo experiments, delineating the unique ability of
WIA in assessing the hemodynamic effects of the device,
highlighting the relationship of device inﬂation and
deﬂation to wave propagation in the aorta. The current
study represents the ﬁrst application of WIA to pressure
and ﬂow measurements in the coronary circulation during
counterpulsation in humans. We have demonstrated that
IABP therapy is associated with a characteristic WIA
morphology, with 2 unique diastolic waves observed, the
ﬁrst, a further FCW, corresponds with inﬂation of the
balloon, and the second with balloon deﬂation. These
novel parameters allow comprehensive assessment of the
effects of IABP therapy integrated with innate micro-
vascular and contractile function and may prove to be
useful in future counterpulsation research, aimed atFigure 5. Relationship of MR With Microcirculatory BEW
(A, B) Microvascular resistance (MR) and BEW during basal conditions. (C, D) MR andistinguishing responders from nonresponders and for
assessing the relative efﬁcacy of newer iterations of pul-
satile assist devices.
Using these techniques, we have demonstrated that IABP
augmentation of aortic and distal coronary pressure does not
necessarily translate to an improvement in coronary ﬂow or
perfusion of the heart, as previously thought. Instead, we
have shown that the energy driving myocardial perfusion
during counterpulsation is entirely different to the patterns
in unassisted conditions, with the added beneﬁcial energy of
the IABP-FCW being offset by a decrease in the BEW
(in turn due to an increase in microvascular resistance due
to autoregulation) such that net coronary ﬂow remains un-
changed. In contrast, during hyperemic conditions, when
autoregulation is disabled, there is no diminution of the
BEW during counterpulsation, such that the effect of
the IABP-FCW and the BEW are summative, resulting
in augmentation of coronary ﬂow. In the presence ofd BEW in hyperemia. Abbreviations as in Figures 2 and 3.
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639hyperemia, the energy from the balloon inﬂation (IABP-
FCW) related linearly to the increase in peak coronary ﬂow
velocity (DAPV) (Fig. 5). These observations may explain
the lack of beneﬁt seen when the IABP is employed pro-
phylactically rather than in cases when autoregulatory
mechanisms have been rendered dysfunctional, such as in
the presence of persistent ischemia or shock.
We have described a novel experimental model to char-
acterize the effects of intra-aortic balloon counterpulsation
on myocardial perfusion and to compare its efﬁcacy in 2
settings, with and without functioning autoregulation.
These techniques have the potential to be applied to
investigation of other circulatory assist devices, including
those that allow direct left ventricular unloading and itera-
tions of the balloon pump itself, in a variety of clinical and
experimental settings.
Study limitations. This was a small, single center study, but
it is the ﬁrst in human study to describe the relationship and
effects of the use of intra-aortic balloon counterpulsation on
coronary wave intensity and the effects of modulating cor-
onary autoregulation on the utility of IABP therapy. As a
consequence of the small sample sizes and the use of un-
adjusted statistical tests adopted within the studies, there is
potential for a type 1 error affecting the results. Therefore,
further investigation is warranted to conﬁrm these initial
ﬁndings.
Conclusions
Autoregulation ameliorates the effect of IABP on coro-
nary ﬂow by increasing microvascular resistance in
response to increased distal coronary pressure. However,
during hyperemic conditions, IABP augments myo-
cardial perfusion, principally due to a diastolic FCW
caused by balloon inﬂation. These ﬁndings suggest IABP
will be of greatest beneﬁt when regional microcirculatory
reserve is exhausted.
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